A Study to Learn About the Effects of Cemsidomide in Combination With Elranatamab in Relapsed/Refractory Multiple Myeloma Subjects
← catalyst calendarNCT07280013 · readout ≤ 864 d
Sponsored by C4 Therapeutics, Inc. (industry) · CCCC — their whole pipeline →.
Phase
Phase 1
Status
Recruiting
Study type
Interventional
Design
Na · None · Treatment
Enrollment
60estimated
Sites
20
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2026-02-06 | actual | When the study began enrolling |
| Primary completion | Dec 2028 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Jun 2029 | estimated | The whole study's end, after follow-up |
| First posted | 2025-12-12 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-08-12 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Multiple Myeloma (MM)
Interventions
- Drug: Cemsidomide
- Biological: Elranatamab — also filed as o PF-06863135 o ELREXFIO
Primary outcomes
what the primary-completion date above is the date OFSafety and tolerability of cemsidomide in combination with elranatamab
measured Cycle 1 approximately 28 days
Safety and tolerability of cemsidomide in combination with elranatamab
measured Baseline through 30 days after discontinuation of study treatment
Permalink · CCCC's whole pipeline · Catalyst calendar · Every registered study · What changed